Pharmaceutical and dietary composition

• US 4,681,896 A
• Filed: 01/31/1984
• Issued: 07/21/1987
• Est. Priority Date: 02/01/1983
• Status: Expired due to Term

• Current Assignee: Efamol Ltd.
• Original Assignee: Efamol Ltd.
• Inventors: Horrobin, David F.
• Primary Examiner(s): Brown, Johnnie R.
• Assistant Examiner(s): Rollins, Jr., John W.
• Application Number:
  US06/575,744
• Time in Patent Office: 1,267 Days
• Field of Search: 514/552, 514/861
• US Class Current: 514/552
• CPC Class Codes: A23D 9/00 Other edible oils or fats, e.g. shortenings, cooking oils
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/20 having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• CPC Class Codes: A61K 31/23 of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• CPC Class Codes: A61K 31/557 Eicosanoids, e.g. leukotrienes or prostaglandins
• CPC Class Codes: A61K 35/60 Fish, e.g. seahorses; Fish eggs
• CPC Class Codes: A61K 36/185 Magnoliopsida (dicotyledons)
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 27/16 Otologicals
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14

Abstract

A method of treatment of atopic disorders, including eczema, asthma, allergies (especially allergic rhinitis), migraine and disorders associated with atopy including Crohn'"'"'s disease, ulcerative colitis, otitis media, nephrotic syndrome, or benign breast disease, or breast or other cancer, or diabetes, or alcoholism, with effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-6 or 22:5n-6) and one or more of the metabolites of α-linolenic acid (18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) are administered as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto alone or in an acceptable pharmaceutical carrier or diluent.

Claims

1. A method of treating an atopic disorder wherein

(1) an effective amount of a metabolite of linoleic acid selected from the group consisting of GLA, DGLA, AA a 22:

4n-6 essential fatty acid and a 22;

5 n-6 essential fatty acid, and

(2) an effective amount of a metabolite of alpha-linolenic acid selected from the group consisting of 18;

4n-3, 20;

4n-3, 20;

5n-3, 22;

5n-3 and 22;

6n-3 essential fatty acids,

are administered alone or in an acceptable pharmaceutical carrier or diluent to a person suffering from said disorder.

2. A method according to claim 1, wherein said disorder is eczema.

3. A method according to claim 2 wherein one or both said metabolites are in the form of an ester, salt, amide or other derivative convertible in the body thereto.

4. A method according to claim 2, wherein at least two of said metabolites of linoleic acid are administered.

5. A method according to claim 2, wherein at least two of said metabolites of alpha-linoleic acid are administered.

6. A method according to claim 2, wherein GLA or DGLA is administered.

7. A method according to claim 2, wherein said amount of each acid is 1 mg to 50 g/day.

8. A method according to claim 7, wherein said amount of each acid is 50 mg to 5 g/day.

9. A method according to claim 1, wherein one or both said metabolites are in the form of an ester, salt, amide or other derivative convertible in the body thereto.

10. A method according to claim 1, wherein at least two of said metabolites of linoleic acid are administered.

11. A method according to claim 1, wherein at least two of said metabolites of alpha-linolenic acid are administered.

12. A method according to claim 1, wherein GLA or DGLA is administered.

13. A method according to claim 1, wherein said amount of each acid is 1 mg to 50 g/day.

14. A method according to claim 13, wherein said amount of each acid is 50 mg to 5 g/day.